Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth

Adam, 1999, Amphiregulin is coordinately expressed with heparin-binding epidermal growth factor-like growth factor in the interstitial smooth muscle of the human prostate, Endocrinology, 140, 5866, 10.1210/endo.140.12.7221

Agus, 1999, Prostate cancer cell cycle regulators, J. Natl. Cancer Inst., 91, 1869, 10.1093/jnci/91.21.1869

Agus, 1999, Prostate cancer cell cycle regulators, J. Natl. Cancer Inst., 91, 1869, 10.1093/jnci/91.21.1869

Agus, 1999, Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models, Cancer Res., 59, 4761

Agus, 2000, A potential role for activated HER-2 in prostate cancer, Semin. Oncol., 27, 76

Alimandi, 1995, Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas, Oncogene, 10, 1813

Arteaga, 2001, The epidermal growth factor receptor, J. Clin. Oncol., 19, 32S

Baselga, 2000, ZD1839 (`Iressa') as an anticancer agent, Drugs, 60, 33, 10.2165/00003495-200060001-00004

Baselga, 1998, Recombinant humanized anti-HER2 antibody (Herceptin™) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts, Cancer Res., 58, 2825

Beerli, 1996, Epidermal growth factor-related peptide activate distinct subsets of ErbB receptors and differ in their biological activities, J. Biol. Chem., 271, 6071, 10.1074/jbc.271.11.6071

Beerli, 1994, Intracellular expression of single chain antibodies reverts ErbB-2 transformation, J. Biol. Chem., 269, 23931, 10.1016/S0021-9258(19)51027-4

Beerli, 1995, Neu differentiation factor activation of ErbB-3 and ErbB-4 is cell specific and displays a differential requirement for ErbB-2, Mol. Cell. Biol., 15, 6496, 10.1128/MCB.15.12.6496

Ben-Bassat, 2000, Inhibitors of tyrosine kinases in the treatment of psoriasis, Curr. Pharm. Des., 6, 933, 10.2174/1381612003400182

Chung, 1993, Implications of stromal-epithelial interaction in human prostate cancer growth, progression and differentiation, Semin. Cancer Biol., 4, 183

Clynes, 2000, Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets, Nat. Med., 6, 443, 10.1038/74704

Cobleigh, 1999, Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease, J. Clin. Oncol., 17, 2639, 10.1200/JCO.1999.17.9.2639

Craft, 1999, A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase, Nat. Med., 5, 280, 10.1038/6495

Cullen, 1992, Stromal-epithelial interactions in breast cancer, Cancer Treat. Res., 61, 413, 10.1007/978-1-4615-3500-3_20

Cunha, 1994, Role of mesenchymal-epithelial interactions in normal and abnormal development of the mammary gland and prostate, Cancer, 74, 1030, 10.1002/1097-0142(19940801)74:3+<1030::AID-CNCR2820741510>3.0.CO;2-Q

deFazio, 2000, Expression of c-erbB receptors, heregulin and oestrogen receptor in human breast cell lines, Int. J. Cancer, 87, 487, 10.1002/1097-0215(20000815)87:4<487::AID-IJC5>3.0.CO;2-J

Duque, 2001, Heparin-binding epidermal growth factor-like growth factor is an autocrine mediator of human prostate stromal cell growth in vitro, J. Urol., 165, 284, 10.1097/00005392-200101000-00080

Fendly, 1990, Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product, Cancer Res., 50, 1550

Fitzpatrick, 1998, Formation of a high affinity heregulin binding site using the soluble extracellular domains of ErbB2 with ErbB3 or ErbB4, FEBS Lett., 431, 102, 10.1016/S0014-5793(98)00737-6

Gibson, 1996, A novel method for real time quantitative PCR, Genome Res., 6, 986, 10.1101/gr.6.10.995

Graus-Porta, 1997, ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling, EMBO J., 16, 1647, 10.1093/emboj/16.7.1647

Grossmann, 2001, Androgen receptor signaling in androgen-refractory prostate cancer, J. Natl. Cancer Inst., 93, 1687, 10.1093/jnci/93.22.1687

Guy, 1994, Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity, Proc. Natl. Acad. Sci. USA, 91, 8132, 10.1073/pnas.91.17.8132

Heid, 1996, Real time quantitative PCR, Genome. Res., 6, 986, 10.1101/gr.6.10.986

Hidalgo, 2001, Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies, J. Clin. Oncol., 19, 3267, 10.1200/JCO.2001.19.13.3267

Jones, 1998, Binding interaction of the heregulinβ EGF-domain with ErbB3 and ErbB4 receptors assessed by alanine scanning mutagenesis, J. Biol. Chem., 273, 11667, 10.1074/jbc.273.19.11667

Jones, 1999, Binding specificities and affinities of egf domains for ErbB receptors, FEBS Lett., 447, 227, 10.1016/S0014-5793(99)00283-5

Kallakury, 1998, Correlation of p34cdc2 cyclin-dependent kinase overexpression, CD44s downregulation, and HER-2/neu oncogen amplification with recurrence in prostatic adenocarcinomas, J. Clin. Oncol., 16, 1302, 10.1200/JCO.1998.16.4.1302

Kalmes, 2000, Heparin blockade of thrombin-induced smooth muscle cell migration involves inhibition of epidermal growth factor (EGF) receptor transactivation by heparin-binding EGF-like growth factor, Circ. Res., 87, 92, 10.1161/01.RES.87.2.92

Karunagaran, 1996, ErbB-2 is a common auxiliary subunit of NDF and EGF receptors, EMBO J., 15, 254, 10.1002/j.1460-2075.1996.tb00356.x

Kelley, 1992, Antigen binding thermodynamics and antiproliferatvie effects of chimeric and humanized anti-p185HER2 antibody Fab fragments, Biochemisty, 31, 5434, 10.1021/bi00139a003

Kim, 1999, EGF receptor signaling in prostate morphogenisis and tumorigenesis, Histol. Histopathol., 14, 1175

Klapper, 1999, The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors, Proc. Natl. Acad. Sci. USA, 96, 4995, 10.1073/pnas.96.9.4995

Lenferink, 1998, Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers, EMBO J., 17, 3385, 10.1093/emboj/17.12.3385

Lewis, 1996, Growth regulation of human breast and ovarian tumor cells by heregulin, Cancer Res., 56, 1457

Marte, 1995, NDF/heregulin activates MAP kinase and p70/p85 S6 kinase during proliferation or differentiation of mammary epithelial cells, Oncogene, 10, 167

Mendelsohn, 2000, The EGF receptor family as targets for cancer therapy, Oncogene, 19, 6550, 10.1038/sj.onc.1204082

Molina, 2001, Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells, Cancer Res., 61, 4744

Nagabhushan, 1996, CWR22, Cancer Res., 56, 3042

Olayioye, 1998, ErbB-1 and ErbB-2 acquire distinct signaling properties dependent upon their dimerization partner, Mol. Cell. Biol., 18, 5042, 10.1128/MCB.18.9.5042

Osman, 2001, HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer, Clin. Cancer Res., 7, 2643

Oxley, 2002, Her-2/neu oncogene amplification in clinically localised prostate cancer, J. Clin. Pathol., 55, 118, 10.1136/jcp.55.2.118

Pegram, 1999, Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers, Oncogene, 18, 2241, 10.1038/sj.onc.1202526

Pietras, 1998, Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs, Oncogene, 17, 2235, 10.1038/sj.onc.1202132

Pinkas-Kramarski, 1996, Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions, EMBO J., 15, 2452, 10.1002/j.1460-2075.1996.tb00603.x

Pinkas-Kramarski, 1996, Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions, EMBO J., 15, 2452, 10.1002/j.1460-2075.1996.tb00603.x

Reese, 2001, HER2 protein expression and gene amplification in androgen-independent prostate cancer, Am. J. Clin. Pathol., 116, 234, 10.1309/VXKK-YVRH-9B11-YDPT

Ross, 1997, HER-2/neu gene amplification status in prostate cancer by fluorescence in situ hybridization, Hum. Pathol., 28, 827, 10.1016/S0046-8177(97)90157-X

Sadick, 1996, Analysis of heregulin-induced ErbB2 phosphorylation with a high throughput “Kinase Receptor Activation” (KIRA) ELISA, Anal. Biochem., 235, 207, 10.1006/abio.1996.0114

Savinainen, 2002, Expression and gene copy number analysis of ERBB2 oncogene in prostate cancer, Am. J. Pathol., 160, 339, 10.1016/S0002-9440(10)64377-5

Schaefer, 1997, γ-heregulin, Oncogene, 15, 1385, 10.1038/sj.onc.1201317

Scher, 1995, Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor alpha in the progression of prostatic neoplasms, Clin. Cancer Res., 1, 545

Shawver, 2002, Smart drugs, Cancer Cell, 1, 117, 10.1016/S1535-6108(02)00039-9

Shi, 2001, Her-2/neu expression in prostate cancer, J. Urol., 166, 1514, 10.1016/S0022-5347(05)65822-3

Signoretti, 2000, Her-2-neu expression and progression toward androgen independence in human prostate cancer, J. Natl. Cancer Inst., 92, 1918, 10.1093/jnci/92.23.1918

Slamon, 1987, Human breast cancer, Science, 235, 177, 10.1126/science.3798106

Slamon, 2001, Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2, N. Engl. J. Med., 344, 783, 10.1056/NEJM200103153441101

Sliwkowski, 1994, Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin, J. Biol. Chem., 269, 14661, 10.1016/S0021-9258(17)36676-0

Sliwkowski, 1999, Nonclinical studies addressing the mechanism of action of trastuzumab (herceptin), Semin. Oncol., 26,, 60

Soltoff, 1994, ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor, Mol. Cell. Biol., 14, 3550, 10.1128/MCB.14.6.3550

Torring, 2000, Increased expression of heparin binding EGF (HB-EGF), amphiregulin, TGF alpha and epiregulin in androgen-independent prostate cancer cell lines, Anticancer Res., 20, 91

Tzahar, 1998, The ErbB-2/HER2 oncogenic receptor of adenocarcinomas, Biochim. Biophys. Acta, 1377, M25

Wainstein, 1994, CWR22, Cancer Res., 54, 6049

Wallasch, 1995, Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3, EMBO J., 14, 4267, 10.1002/j.1460-2075.1995.tb00101.x

Wells, 1999, EGF receptor, Int. J. Biochem. Cell Biol., 31, 637, 10.1016/S1357-2725(99)00015-1

Wen, 2000, HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway, Cancer Res., 60, 6841

Woodburn, 1999, The epidermal growth factor receptor and its inhibition in cancer therapy, Pharmacol. Ther., 82, 241, 10.1016/S0163-7258(98)00045-X

Worthylake, 1999, ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both ErbB2 and epidermal growth factor receptors, J. Biol. Chem., 274, 8865, 10.1074/jbc.274.13.8865

Yarden, 2001, Untangling the ErbB signalling network, Nat. Rev. Mol. Cell Biol., 2, 127, 10.1038/35052073

Yeh, 1999, From HER2/Neu signal cascade to androgen receptor and its coactivators, Proc. Natl. Acad. Sci. USA, 96, 5458, 10.1073/pnas.96.10.5458